Literature DB >> 21300334

Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm injection treatment cycle: impact on ovarian stimulation. A pilot study.

Christophe Blockeel1, Arianna Riva, Michel De Vos, Patrick Haentjens, Paul Devroey.   

Abstract

OBJECTIVE: To investigate the impact on the number of cumulus-oocyte complexes (COC) when a 3-day course of GnRH antagonist treatment precedes the initiation of controlled ovarian stimulation with gonadotropins in a GnRH antagonist protocol for IVF/intracytoplasmic sperm injection (ICSI).
DESIGN: Randomized controlled trial.
SETTING: Tertiary referral center. PATIENT(S): Sixty-nine women undergoing controlled ovarian hyperstimulation for IVF/ICSI. INTERVENTION(S): The control group (n = 36) received a standard treatment with daily injections of recombinant FSH (rFSH), starting on day 2 of the cycle at a dose of 150-225 IU/day, and GnRH antagonists from cycle day 7 onward. In the pretreatment group (n = 33), a GnRH antagonist was administered from day 2 of the menstrual cycle onward during 3 consecutive days; thereafter controlled ovarian stimulation was initiated with the same protocol as used in the control group. MAIN OUTCOME MEASURE(S): The primary endpoint was the number of COCs at egg retrieval. RESULT(S): Both groups had comparable baseline characteristics. The duration of rFSH stimulation and consumption of gonadotropins were similar in both groups. The number of COCs was higher in the pretreatment group (12.8; SD, 7.8) compared with in the control group (9.9; SD, 4.9), although this increment was not significant (between-group difference of 2.9 [95% confidence interval {CI} -0.2 to 6.0]). The ongoing pregnancy rates per started cycle of 14/33 (42%) versus 12/36 (33%) for pretreatment versus control did not differ significantly (between-group difference, 9.1%; 95% CI, -13% to 30%). CONCLUSION(S): Among women under 36 years old, early follicular phase GnRH antagonist pretreatment in a fixed GnRH antagonist protocol results in a trend toward a higher number of retrieved oocytes but does not yield significantly higher pregnancy rates.
Copyright © 2011 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21300334     DOI: 10.1016/j.fertnstert.2011.01.028

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  10 in total

1.  A novel "delayed start" protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders.

Authors:  Hakan Cakmak; Nam D Tran; A Musa Zamah; Marcelle I Cedars; Mitchell P Rosen
Journal:  Fertil Steril       Date:  2014-03-14       Impact factor: 7.329

Review 2.  Efficacy of the delayed start antagonist protocol for controlled ovarian stimulation in Bologna poor ovarian responders: a systematic review and meta-analysis.

Authors:  Shuang Yang; Nenghui Liu; Yanping Li; Lei Zhang; Rongya Yue
Journal:  Arch Gynecol Obstet       Date:  2020-11-24       Impact factor: 2.344

3.  Optimisation of the follicular phase in IVF/ICSI.

Authors:  C Blockeel; P Devroey
Journal:  Facts Views Vis Obgyn       Date:  2012

4.  Pregnancy outcome in delayed start antagonist versus microdose flare GnRH agonist protocol in poor responders undergoing IVF/ICSI: An RCT.

Authors:  Robab Davar; Nosrat Neghab; Elham Naghshineh
Journal:  Int J Reprod Biomed       Date:  2018-04

5.  Evaluation of GnRH antagonist pretreatment before ovarian stimulation in a GnRH antagonist protocol in normal ovulatory women undergoing IVF/ICSI: a randomized controlled trial.

Authors:  Yisheng Zhang; Liling Liu; Jie Qin; Hongyi Huang; Lintao Xue; Shikai Wang; Weihong Tan
Journal:  Reprod Biol Endocrinol       Date:  2021-10-12       Impact factor: 5.211

6.  Effect of early GnRH antagonist administration on assisted reproductive technique outcomes in normal responders.

Authors:  Manal Al-Obaidi
Journal:  J Med Life       Date:  2022-02

7.  Follicular phase cycle programming using estradiol in oocyte donors-a convenient and effective approach.

Authors:  Manish Banker; Parul Arora; Jwal Banker; Reena Gupta; Sandeep Shah
Journal:  F S Rep       Date:  2022-01-05

8.  A Proof-of-Concept Clinical Trial of A Single Luteal Use of Long-Acting Gonadotropin-Releasing Hormone Antagonist Degarelix in Controlled Ovarian Stimulation for In Vitro Fertilization: Long Antagonist Protocol.

Authors:  Evangelos G Papanikolaou; Hakan Yarali; Evi Timotheou; Michael Grynberg; Odysseas Zafeiratis; Herman Tournaye; Robert Najdecki
Journal:  Front Endocrinol (Lausanne)       Date:  2018-03-01       Impact factor: 5.555

9.  Evaluation of pretreatment with Cetrotide in an antagonist protocol for patients with PCOS undergoing IVF/ICSI cycles: a randomized clinical trial.

Authors:  Maryam Eftekhar; Ramesh Baradaran Bagheri; Nosrat Neghab; Robabe Hosseinisadat
Journal:  JBRA Assist Reprod       Date:  2018-09-01

10.  ESHRE guideline: ovarian stimulation for IVF/ICSI.

Authors:  The Eshre Guideline Group On Ovarian Stimulation; Ernesto Bosch; Simone Broer; Georg Griesinger; Michael Grynberg; Peter Humaidan; Estratios Kolibianakis; Michal Kunicki; Antonio La Marca; George Lainas; Nathalie Le Clef; Nathalie Massin; Sebastiaan Mastenbroek; Nikolaos Polyzos; Sesh Kamal Sunkara; Tanya Timeva; Mira Töyli; Janos Urbancsek; Nathalie Vermeulen; Frank Broekmans
Journal:  Hum Reprod Open       Date:  2020-05-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.